Diagnostic karyotypic data for 812 assessable patients according to whether they progressed
| Lesion . | No progression . | Progression . | Percentage progressing . |
|---|---|---|---|
| Normal (no Ph) | 6 | 0 | |
| Ph only | 625 | 15 | 2.3 |
| 3-way Ph* | 54 | 1 | 1.9 |
| 4-way Ph* | 5 | 0 | |
| Loss of Y | 17 | 0 | |
| Original major route lesion | 14 | 3 | 17.6 |
| Trisomy 8 | 5† | 2‡ | |
| Additional Ph | 3 | 1‡ | |
| Isochromosome 17q | 6 | 1 | |
| Trisomy 19 | 1† | 0 | |
| Additional lesions | 9 | 5 | 35.7 |
| Trisomy 21 | 0 | 0 | |
| 3q26.2 lesion | 0 | 1 | |
| Monosomy 7/7q− | 2§ | 0 | |
| 11q23 lesion | 2 | 1 | |
| Complex karyotype | 7§ | 3§ | |
| Other lesion | 20 | 0 | |
| Total unique patients† | 741 | 22 | 2.9 |
| Karyotype unavailable | 48 | 1 | 2.0 |
| Lesion . | No progression . | Progression . | Percentage progressing . |
|---|---|---|---|
| Normal (no Ph) | 6 | 0 | |
| Ph only | 625 | 15 | 2.3 |
| 3-way Ph* | 54 | 1 | 1.9 |
| 4-way Ph* | 5 | 0 | |
| Loss of Y | 17 | 0 | |
| Original major route lesion | 14 | 3 | 17.6 |
| Trisomy 8 | 5† | 2‡ | |
| Additional Ph | 3 | 1‡ | |
| Isochromosome 17q | 6 | 1 | |
| Trisomy 19 | 1† | 0 | |
| Additional lesions | 9 | 5 | 35.7 |
| Trisomy 21 | 0 | 0 | |
| 3q26.2 lesion | 0 | 1 | |
| Monosomy 7/7q− | 2§ | 0 | |
| 11q23 lesion | 2 | 1 | |
| Complex karyotype | 7§ | 3§ | |
| Other lesion | 20 | 0 | |
| Total unique patients† | 741 | 22 | 2.9 |
| Karyotype unavailable | 48 | 1 | 2.0 |
Two patients of the original 814 who never received trial drug are excluded.
One patient had both a 3-way and a 4-way Ph translocation.
One nonprogressing patient had both trisomy 8 and trisomy 19.
One progressing patient had both trisomy 8 and a second Ph translocation.
Of patients with complex karyotypes, 2 nonprogressing patients also had monosomy 7 (one of whom also had isochromosome 17q); furthermore, 1 patient without progression had trisomy 8 and 19, and 2 progressing patients also had trisomy 8 (one of whom had a second Ph translocation as well).